Ratings by JPMorgan (Anupam Rama)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/16/2026 | CAMP4 Therapeutics Corp | CAMP | Upgrade | Overweight (Neutral) |
4.19 (4.36) |
4.06% | Details | |
| 6/9/2026 | Nuvalent | NUVL | Downgrade | Neutral (Overweight) |
88.49 (123.44) |
39.5% | Details | |
| 6/1/2026 | Replimune Group | REPL | Upgrade | Neutral (Underweight) |
4.68 (11.42) |
144.02% | Details | |
| 5/29/2026 | Replimune Group | REPL | Upgrade | Neutral (Underweight) |
4.68 (4.68) |
0% | Details | |
| 5/20/2026 | Zai Lab | ZLAB | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/20/2026 | Ultragenyx Pharma | RARE | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/19/2026 | Solid Biosciences | SLDB | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/23/2026 | First Tracks Biotherapeutics | TRAX | New Coverage | Overweight (N/A) |
17.00 (17.78) |
4.59% | Details | |
| 4/15/2026 | Travere Therapeutics | TVTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/13/2026 | Replimune Group | REPL | Downgrade | Underweight (Neutral) |
5.91 (4.68) |
-20.81% | Details | |
| 4/2/2026 | Kodiak Sciences Inc. | KOD | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/2/2026 | AnaptysBio | ANAB | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/1/2026 | Apellis Pharmaceuticals | APLS | Downgrade | Neutral (Overweight) |
17.09 (41.03) |
140.08% | Details | |
| 3/31/2026 | Maze Therapeutics | MAZE | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/25/2026 | Travere Therapeutics | TVTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/25/2026 | Solid Biosciences | SLDB | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/18/2026 | Zai Lab | ZLAB | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/18/2026 | Olema Pharmaceuticals | OLMA | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/18/2026 | Erasca Inc | ERAS | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/16/2026 | CytomX Therapeutics | CTMX | Upgrade | Overweight (Neutral) |
4.68 (3.15) |
-32.69% | Details | |
| 3/12/2026 | Ultragenyx Pharma | RARE | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/12/2026 | Neurocrine Bio. | NBIX | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/11/2026 | ORIC Pharmaceuticals | ORIC | Maintain | Overweight (N/A) |
|
Details | ||
| 3/11/2026 | Day One Biopharmaceuticals | DAWN | Downgrade | Neutral (Overweight) |
21.33 (21.53) |
0.94% | Details | |
| 3/10/2026 | BridgeBio Pharma | BBIO | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/9/2026 | Syndax Pharmaceuticals | SNDX | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/5/2026 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/3/2026 | Enanta Pharmaceuticals | ENTA | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/3/2026 | Agomab Therapeutics | AGMB | New Coverage | Overweight (N/A) |
16.02 (11.94) |
-25.47% | Details | |
| 2/17/2026 | Neurocrine Bio. | NBIX | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/5/2026 | Zai Lab | ZLAB | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/27/2026 | Vera Therapeutics | VERA | Maintain | Overweight (N/A) |
|
Details | ||
| 1/27/2026 | Sarepta Therapeutics | SRPT | Maintain | Neutral (N/A) |
|
Details | ||
| 1/21/2026 | BridgeBio Pharma | BBIO | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/12/2026 | Neurocrine Bio. | NBIX | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/9/2025 | Vor Biopharma, Inc. | VOR | New Coverage | Overweight (N/A) |
8.18 (8.18) |
0% | Details | |
| 12/9/2025 | Vor Biopharma, Inc. | VOR | New Coverage | Overweight (N/A) |
8.18 (14.85) |
81.54% | Details | |
| 11/19/2025 | Zai Lab | ZLAB | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/19/2025 | Ultragenyx Pharma | RARE | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/18/2025 | ORIC Pharmaceuticals | ORIC | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/18/2025 | Olema Pharmaceuticals | OLMA | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/17/2025 | Cidara Therapeutics | CDTX | Downgrade | Neutral (Overweight) |
105.99 (221.38) |
108.87% | Details | |
| 11/17/2025 | Biomea Fusion Inc. | BMEA | Downgrade | Underweight (Neutral) |
1.29 (1.23) |
-4.65% | Details | |
| 11/14/2025 | Enanta Pharmaceuticals | ENTA | New Coverage | Overweight (N/A) |
11.93 (14.06) |
17.85% | Details | |
| 11/12/2025 | Syndax Pharmaceuticals | SNDX | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/12/2025 | Rapt Therapeutics | RAPT | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/7/2025 | Vera Therapeutics | VERA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/7/2025 | Day One Biopharmaceuticals | DAWN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/7/2025 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 11/6/2025 | Amicus Therapeutics | FOLD | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/5/2025 | Solid Biosciences | SLDB | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/5/2025 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/24/2025 | Kodiak Sciences Inc. | KOD | Upgrade | Overweight (Neutral) |
18.05 (37.05) |
105.26% | Details | |
| 10/23/2025 | Ideaya Biosciences | IDYA | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/20/2025 | Replimune Group | REPL | Upgrade | Neutral (Underweight) |
4.50 (5.91) |
31.33% | Details | |
| 10/20/2025 | Rapt Therapeutics | RAPT | Upgrade | Overweight (Neutral) |
29.34 (58.02) |
97.75% | Details | |
| 10/10/2025 | Cidara Therapeutics | CDTX | New Coverage | Overweight (N/A) |
98.51 (105.99) |
7.59% | Details | |
| 9/29/2025 | Maze Therapeutics | MAZE | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/19/2025 | Replimune Group | REPL | Downgrade | Underweight (Neutral) |
5.71 (4.50) |
-21.19% | Details | |
| 9/3/2025 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 9/3/2025 | Ideaya Biosciences | IDYA | Maintain | Overweight (N/A) |
|
Details | ||
| 8/14/2025 | Maze Therapeutics | MAZE | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/14/2025 | Kodiak Sciences Inc. | KOD | Upgrade | Neutral (Underweight) |
8.52 (18.05) |
111.85% | Details | |
| 8/13/2025 | Solid Biosciences | SLDB | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/13/2025 | ORIC Pharmaceuticals | ORIC | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/13/2025 | Olema Pharmaceuticals | OLMA | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/8/2025 | Rapt Therapeutics | RAPT | Maintain | Neutral (Neutral) |
|
Details | ||
| 8/8/2025 | BridgeBio Pharma | BBIO | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/7/2025 | Vera Therapeutics | VERA | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/7/2025 | Cogent | COGT | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/6/2025 | Neurocrine Bio. | NBIX | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/6/2025 | Syndax Pharmaceuticals | SNDX | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/6/2025 | Kiniksa | KNSA | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/30/2025 | Rapt Therapeutics | RAPT | Upgrade | Neutral (Underweight) |
12.67 (29.34) |
131.57% | Details | |
| 7/29/2025 | Sarepta Therapeutics | SRPT | Upgrade | Neutral (Underweight) |
11.93 (17.26) |
44.68% | Details | |
| 7/28/2025 | Ideaya Biosciences | IDYA | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/25/2025 | Sarepta Therapeutics | SRPT | Downgrade | Underweight (Neutral) |
13.32 (11.93) |
-10.44% | Details | |
| 7/24/2025 | AnaptysBio | ANAB | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/22/2025 | Replimune Group | REPL | Downgrade | Neutral (Overweight) |
12.33 (5.71) |
-53.69% | Details | |
| 7/21/2025 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 7/16/2025 | Replimune Group | REPL | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/10/2025 | Cogent | COGT | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/10/2025 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 6/6/2025 | Vera Therapeutics | VERA | Maintain | Overweight (N/A) |
|
Details | ||
| 6/3/2025 | Replimune Group | REPL | Maintain | Overweight (N/A) |
|
Details | ||
| 6/2/2025 | Vera Therapeutics | VERA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/23/2025 | Ultragenyx Pharma | RARE | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/23/2025 | Replimune Group | REPL | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/22/2025 | Ideaya Biosciences | IDYA | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/20/2025 | ORIC Pharamceuticals | ORIC | Maintain | Overweight (N/A) |
|
Details | ||
| 5/20/2025 | Sarepta Therapeutics | SRPT | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/20/2025 | Maze Therapeutics | MAZE | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/16/2025 | Vera Therapeutics | VERA | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/16/2025 | Travere Therapeutics | TVTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/15/2025 | Neurocrine Bio. | NBIX | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/13/2025 | ORIC Pharamceuticals | ORIC | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/13/2025 | Day One Biopharmaceuticals | DAWN | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/28/2025 | Olema Pharmaceuticals | OLMA | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/27/2025 | Ultragenyx Pharma | RARE | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/26/2025 | Neurocrine Bio. | NBIX | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/24/2025 | BridgeBio Pharma | BBIO | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/20/2025 | Syndax Pharmaceuticals | SNDX | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/18/2025 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 3/18/2025 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/13/2025 | Solid Biosciences | SLDB | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/13/2025 | Zai Lab | ZLAB | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/5/2025 | Day One Biopharmaceuticals | DAWN | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/5/2025 | AnaptysBio | ANAB | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/4/2025 | Vera Therapeutics | VERA | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/4/2025 | Syndax Pharmaceuticals | SNDX | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/4/2025 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/28/2025 | Nuvalent | NUVL | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/28/2025 | Amicus Therapeutics | FOLD | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/28/2025 | Cogent | COGT | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/26/2025 | Travere Therapeutics | TVTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/26/2025 | Replimune Group | REPL | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/26/2025 | ORIC Pharamceuticals | ORIC | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/25/2025 | Neurocrine Bio. | NBIX | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/25/2025 | Maze Therapeutics | MAZE | New Coverage | Overweight (N/A) |
12.09 (26.41) |
118.44% | Details | |
| 2/6/2025 | ORIC Pharamceuticals | ORIC | Maintain | Overweight (N/A) |
|
Details | ||
| 11/12/2024 | Solid Biosciences | SLDB | Maintain | Overweight (N/A) |
|
Details | ||
| 11/12/2024 | AnaptysBio | ANAB | Maintain | Overweight (N/A) |
|
Details | ||
| 11/12/2024 | Amicus Therapeutics | FOLD | Maintain | Overweight (N/A) |
|
Details | ||
| 11/11/2024 | Rapt Therapeutics | RAPT | Downgrade | Underweight (Neutral) |
2.89 (12.67) |
338.41% | Details | |
| 11/5/2024 | Vera Therapeutics | VERA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/5/2024 | Kiniksa | KNSA | Maintain | Overweight (N/A) |
|
Details | ||
| 10/21/2024 | Zai Lab | ZLAB | Maintain | Overweight (N/A) |
|
Details | ||
| 10/4/2024 | Nuvalent | NUVL | Maintain | Overweight (N/A) |
|
Details | ||
| 9/30/2024 | ProKidney Corp. | PROK | New Coverage | Neutral (N/A) |
2.04 (1.80) |
-11.76% | Details | |
| 9/24/2024 | Replimune Group | REPL | Maintain | Overweight (N/A) |
|
Details | ||
| 9/11/2024 | Kiniksa | KNSA | Maintain | Overweight (N/A) |
|
Details | ||
| 9/4/2024 | Nuvalent | NUVL | Maintain | Overweight (N/A) |
|
Details | ||
| 9/4/2024 | Spring Works Therapeutics | SWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/3/2024 | Vera Therapeutics | VERA | Maintain | Overweight (N/A) |
|
Details | ||
| 8/16/2024 | Amicus Therapeutics | FOLD | Maintain | Overweight (N/A) |
|
Details | ||
| 8/13/2024 | Vera Therapeutics | VERA | Maintain | Overweight (N/A) |
|
Details | ||
| 8/13/2024 | Replimune Group | REPL | Maintain | Overweight (N/A) |
|
Details | ||
| 8/13/2024 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (N/A) |
|
Details | ||
| 8/13/2024 | Travere Therapeutics | TVTX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/8/2024 | Olema Pharmaceuticals | OLMA | Maintain | Overweight (N/A) |
|
Details | ||
| 8/8/2024 | Ideaya Biosciences | IDYA | Maintain | Overweight (N/A) |
|
Details | ||
| 8/7/2024 | G1 Therapeutics | GTHX | Upgrade | Neutral (Underweight) |
4.25 (7.15) |
68.24% | Details | |
| 8/7/2024 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 8/7/2024 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/7/2024 | AnaptysBio | ANAB | Maintain | Overweight (N/A) |
|
Details | ||
| 8/6/2024 | Syndax Pharmaceuticals | SNDX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/6/2024 | Sage Therapeutics | SAGE | Maintain | Neutral (N/A) |
|
Details | ||
| 8/6/2024 | Day One Biopharmaceuticals | DAWN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/25/2024 | Sage Therapeutics | SAGE | Downgrade | Neutral (Overweight) |
13.08 (8.68) |
-33.64% | Details | |
| 7/19/2024 | AnaptysBio | ANAB | Upgrade | Overweight (Neutral) |
34.46 (59.43) |
72.46% | Details | |
| 7/15/2024 | Solid Biosciences | SLDB | Upgrade | Overweight (Neutral) |
8.19 (8.79) |
7.33% | Details | |
| 7/12/2024 | Zai Lab | ZLAB | Maintain | Overweight (N/A) |
|
Details | ||
| 7/12/2024 | Sage Therapeutics | SAGE | Maintain | Overweight (N/A) |
|
Details | ||
| 7/12/2024 | Ideaya Biosciences | IDYA | Maintain | Overweight (N/A) |
|
Details | ||
| 7/10/2024 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/3/2024 | Alnylam Pharmaceuticals | ALNY | Maintain | Neutral (N/A) |
|
Details | ||
| 6/20/2024 | Sage Therapeutics | SAGE | Maintain | Overweight (N/A) |
|
Details | ||
| 6/12/2024 | Spring Works Therapeutics | SWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/12/2024 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (N/A) |
|
Details | ||
| 6/12/2024 | Zai Lab | ZLAB | Maintain | Overweight (N/A) |
|
Details | ||
| 6/12/2024 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 6/12/2024 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/10/2024 | Replimune Group | REPL | Maintain | Overweight (N/A) |
|
Details | ||
| 5/31/2024 | Solid Biosciences | SLDB | Maintain | Neutral (N/A) |
|
Details | ||
| 5/31/2024 | Vera Therapeutics | VERA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/22/2024 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 5/21/2024 | Syndax Pharmaceuticals | SNDX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/15/2024 | Rallybio Corp. | RLYB | Downgrade | Neutral (Overweight) |
1.78 (15.70) |
782.02% | Details | |
| 5/10/2024 | Day One Biopharmaceuticals | DAWN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/10/2024 | ORIC Pharamceuticals | ORIC | Maintain | Overweight (N/A) |
|
Details | ||
| 5/7/2024 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (N/A) |
|
Details | ||
| 5/3/2024 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 5/1/2024 | Sage Therapeutics | SAGE | Maintain | Overweight (N/A) |
|
Details | ||
| 5/1/2024 | Kiniksa | KNSA | Maintain | Overweight (N/A) |
|
Details | ||
| 4/30/2024 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (N/A) |
|
Details | ||
| 4/26/2024 | Alnylam Pharmaceuticals | ALNY | Maintain | Neutral (N/A) |
|
Details | ||
| 4/22/2024 | Day One Biopharmaceuticals | DAWN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/22/2024 | CytomX Therapeutics | CTMX | Upgrade | Neutral (Underweight) |
1.73 (4.68) |
170.52% | Details | |
| 4/17/2024 | Sage Therapeutics | SAGE | Maintain | Overweight (N/A) |
|
Details | ||
| 4/10/2024 | Vera Therapeutics | VERA | Maintain | Overweight (N/A) |
|
Details | ||
| 4/10/2024 | Olema Pharmaceuticals | OLMA | Maintain | Overweight (N/A) |
|
Details | ||
| 4/1/2024 | AnaptysBio | ANAB | Maintain | Neutral (N/A) |
|
Details | ||
| 4/1/2024 | Annexon Biosciences | ANNX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/27/2024 | Rapt Therapeutics | RAPT | Maintain | Neutral (N/A) |
|
Details | ||
| 3/27/2024 | ORIC Pharamceuticals | ORIC | Maintain | Overweight (N/A) |
|
Details | ||
| 3/26/2024 | Sage Therapeutics | SAGE | Maintain | Overweight (N/A) |
|
Details | ||
| 3/20/2024 | Syndax Pharmaceuticals | SNDX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/20/2024 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 3/18/2024 | Amicus Therapeutics | FOLD | Maintain | Overweight (N/A) |
|
Details | ||
| 3/18/2024 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 3/6/2024 | Spring Works Therapeutics | SWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/6/2024 | Nuvalent | NUVL | Maintain | Overweight (N/A) |
|
Details | ||
| 3/6/2024 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (N/A) |
|
Details | ||
| 3/1/2024 | Annexon Biosciences | ANNX | Upgrade | Overweight (Neutral) |
5.49 (5.28) |
-3.83% | Details | |
| 2/27/2024 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 2/23/2024 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/23/2024 | Ideaya Biosciences | IDYA | Maintain | Overweight (N/A) |
|
Details | ||
| 2/21/2024 | Rapt Therapeutics | RAPT | Downgrade | Neutral (Overweight) |
25.97 (2.89) |
-88.87% | Details | |
| 2/1/2024 | Alnylam Pharmaceuticals | ALNY | Maintain | Neutral (N/A) |
|
Details | ||
| 1/22/2024 | Vera Therapeutics | VERA | Maintain | Overweight (N/A) |
|
Details | ||
| 1/22/2024 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 1/19/2024 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/19/2024 | Kiniksa | KNSA | Maintain | Overweight (N/A) |
|
Details | ||
| 1/19/2024 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (N/A) |
|
Details | ||
| 12/22/2023 | Allovir Inc. | ALVR | Downgrade | Underweight (Overweight) |
2.33 (9.81) |
321.03% | Details | |
| 12/8/2023 | Cogent | COGT | New Coverage | Overweight (N/A) |
8.60 (36.31) |
322.21% | Details | |
| 12/6/2023 | Replimune Group | REPL | Maintain | Overweight (N/A) |
|
Details | ||
| 11/30/2023 | Vera Therapeutics | VERA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/30/2023 | Zai Lab | ZLAB | Maintain | Overweight (N/A) |
|
Details | ||
| 11/30/2023 | Rapt Therapeutics | RAPT | Maintain | Overweight (N/A) |
|
Details | ||
| 11/30/2023 | Ideaya Biosciences | IDYA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/22/2023 | Kiniksa | KNSA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/22/2023 | Spring Works Therapeutics | SWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/31/2023 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 10/24/2023 | ORIC Pharamceuticals | ORIC | Maintain | Overweight (N/A) |
|
Details | ||
| 10/24/2023 | Olema Pharmaceuticals | OLMA | Maintain | Overweight (N/A) |
|
Details | ||
| 10/24/2023 | Ideaya Biosciences | IDYA | Maintain | Overweight (N/A) |
|
Details | ||
| 10/17/2023 | Zai Lab | ZLAB | Maintain | Overweight (N/A) |
|
Details | ||
| 10/17/2023 | Syndax Pharmaceuticals | SNDX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/6/2023 | G1 Therapeutics | GTHX | Downgrade | Underweight (Neutral) |
1.14 (7.15) |
527.19% | Details | |
| 10/6/2023 | Apellis Pharmaceuticals | APLS | Upgrade | Overweight (Neutral) |
37.62 (17.09) |
-54.57% | Details | |
| 10/5/2023 | Nuvalent | NUVL | Maintain | Overweight (N/A) |
|
Details | ||
| 9/29/2023 | Amicus Therapeutics | FOLD | Maintain | Overweight (N/A) |
|
Details | ||
| 9/29/2023 | Amicus Therapeutics | FOLD | Maintain | Overweight (N/A) |
|
Details | ||
| 9/15/2023 | Olema Pharmaceuticals | OLMA | Maintain | Overweight (N/A) |
|
Details | ||
| 9/13/2023 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/17/2023 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 8/17/2023 | Ideaya Biosciences | IDYA | Maintain | Overweight (N/A) |
|
Details | ||
| 8/16/2023 | Syndax Pharmaceuticals | SNDX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/16/2023 | Rapt Therapeutics | RAPT | Maintain | Overweight (N/A) |
|
Details | ||
| 8/16/2023 | Generation Bio | GBIO | Maintain | Neutral (N/A) |
|
Details | ||
| 8/10/2023 | Rallybio Corp. | RLYB | Maintain | Overweight (N/A) |
|
Details | ||
| 8/10/2023 | Olema Pharmaceuticals | OLMA | Maintain | Overweight (N/A) |
|
Details | ||
| 8/3/2023 | Apellis Pharmaceuticals | APLS | Downgrade | Neutral (Overweight) |
24.22 (41.03) |
69.41% | Details | |
| 7/25/2023 | Kodiak Sciences Inc. | KOD | Downgrade | Underweight (Neutral) |
7.29 (8.52) |
16.87% | Details | |
| 7/21/2023 | Travere Therapeutics | TVTX | New Coverage | Overweight (N/A) |
15.45 (55.95) |
262.14% | Details | |
| 7/20/2023 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (N/A) |
|
Details | ||
| 7/17/2023 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 6/23/2023 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 6/23/2023 | Nuvalent | NUVL | Maintain | Overweight (N/A) |
|
Details | ||
| 6/15/2023 | Replimune Group | REPL | Maintain | Overweight (N/A) |
|
Details | ||
| 5/25/2023 | Annexon Biosciences | ANNX | Maintain | Neutral (N/A) |
|
Details | ||
| 5/24/2023 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 5/24/2023 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 5/22/2023 | AnaptysBio | ANAB | Upgrade | Neutral (Underweight) |
18.93 (34.46) |
82.04% | Details | |
| 5/15/2023 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 5/12/2023 | Rallybio Corp. | RLYB | Maintain | Overweight (N/A) |
|
Details | ||
| 5/12/2023 | ORIC Pharamceuticals | ORIC | Maintain | Overweight (N/A) |
|
Details | ||
| 5/10/2023 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/10/2023 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (N/A) |
|
Details | ||
| 4/12/2023 | AnaptysBio | ANAB | Maintain | Underweight (N/A) |
|
Details | ||
| 4/12/2023 | Vera Therapeutics | VERA | Maintain | Overweight (N/A) |
|
Details | ||
| 4/4/2023 | Kodiak Sciences Inc. | KOD | Maintain | Neutral (N/A) |
|
Details | ||
| 3/21/2023 | Rapt Therapeutics | RAPT | Maintain | Overweight (N/A) |
|
Details | ||
| 3/21/2023 | ORIC Pharamceuticals | ORIC | Maintain | Overweight (N/A) |
|
Details | ||
| 3/16/2023 | Zai Lab | ZLAB | Maintain | Overweight (N/A) |
|
Details | ||
| 3/13/2023 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 3/13/2023 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (N/A) |
|
Details | ||
| 3/9/2023 | Kiniksa | KNSA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/8/2023 | Rallybio Corp. | RLYB | Maintain | Overweight (N/A) |
|
Details | ||
| 3/7/2023 | Spring Works Therapeutics | SWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/7/2023 | Syndax Pharmaceuticals | SNDX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/7/2023 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 3/3/2023 | Alnylam Pharmaceuticals | ALNY | Maintain | Neutral (N/A) |
|
Details | ||
| 3/3/2023 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 2/28/2023 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 2/28/2023 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 2/28/2023 | Sage Therapeutics | SAGE | Maintain | Overweight (N/A) |
|
Details | ||
| 2/24/2023 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/24/2023 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (N/A) |
|
Details | ||
| 2/24/2023 | Allovir Inc. | ALVR | Maintain | Overweight (N/A) |
|
Details | ||
| 2/24/2023 | Replimune Group | REPL | Maintain | Overweight (N/A) |
|
Details | ||
| 1/30/2023 | G1 Therapeutics | GTHX | Upgrade | Neutral (Underweight) |
6.57 (7.15) |
8.83% | Details | |
| 1/20/2023 | Cyteir Therapeutics | CYT | Downgrade | Neutral (Overweight) |
1.53 (3.02) |
97.39% | Details | |
| 1/3/2023 | Syndax Pharmaceuticals | SNDX | New Coverage | Overweight (N/A) |
24.76 (19.61) |
-20.8% | Details | |
| 12/12/2022 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 12/9/2022 | Rallybio Corp. | RLYB | New Coverage | Overweight (N/A) |
4.76 (15.70) |
229.83% | Details | |
| 12/6/2022 | Sage Therapeutics | SAGE | Maintain | Overweight (N/A) |
|
Details | ||
| 11/18/2022 | Zai Lab | ZLAB | Maintain | Overweight (N/A) |
|
Details | ||
| 11/18/2022 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 11/18/2022 | Vera Therapeutics | VERA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/18/2022 | AnaptysBio | ANAB | Maintain | Underweight (N/A) |
|
Details | ||
| 11/16/2022 | Rapt Therapeutics | RAPT | Maintain | Overweight (N/A) |
|
Details | ||
| 11/16/2022 | Kodiak Sciences Inc. | KOD | Maintain | Neutral (N/A) |
|
Details | ||
| 11/16/2022 | Annexon Biosciences | ANNX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/15/2022 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (N/A) |
|
Details | ||
| 11/11/2022 | Nuvalent | NUVL | Maintain | Overweight (N/A) |
|
Details | ||
| 11/11/2022 | Ideaya Biosciences | IDYA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/10/2022 | Day One Biopharmaceuticals | DAWN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/10/2022 | CytomX Therapeutics | CTMX | Downgrade | Underweight (Overweight) |
1.23 (3.15) |
156.1% | Details | |
| 11/10/2022 | Elevation Oncology | ELEV | Downgrade | Underweight (Neutral) |
0.94 (0.37) |
-60.64% | Details | |
| 11/9/2022 | Spring Works Therapeutics | SWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/8/2022 | G1 Therapeutics | GTHX | Maintain | Underweight (N/A) |
|
Details | ||
| 11/8/2022 | Allovir Inc. | ALVR | Maintain | Overweight (N/A) |
|
Details | ||
| 11/8/2022 | Replimune Group | REPL | Maintain | Overweight (N/A) |
|
Details | ||
| 11/3/2022 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/24/2022 | Alnylam Pharmaceuticals | ALNY | Maintain | Neutral (N/A) |
|
Details | ||
| 9/30/2022 | Solid Biosciences | SLDB | Upgrade | Neutral (Underweight) |
0.47 (8.19) |
1642.55% | Details | |
| 9/29/2022 | Kodiak Sciences Inc. | KOD | Maintain | Neutral (N/A) |
|
Details | ||
| 9/6/2022 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (N/A) |
|
Details | ||
| 8/15/2022 | Atara Biotherapeutics | ATRA | Maintain | Neutral (N/A) |
|
Details | ||
| 8/9/2022 | Alnylam Pharmaceuticals | ALNY | Maintain | Neutral (N/A) |
|
Details | ||
| 8/8/2022 | Elevation Oncology | ELEV | Downgrade | Neutral (Overweight) |
1.33 (0.37) |
-72.18% | Details | |
| 8/2/2022 | Ultragenyx Pharma | RARE | New Coverage | Overweight (N/A) |
53.28 (28.76) |
-46.02% | Details | |
| 8/2/2022 | Sage Therapeutics | SAGE | New Coverage | Overweight (N/A) |
34.41 (13.08) |
-61.99% | Details | |
| 8/2/2022 | CytomX Therapeutics | CTMX | New Coverage | Overweight (N/A) |
1.43 (3.15) |
120.28% | Details | |
| 7/13/2022 | Atara Biotherapeutics | ATRA | Downgrade | Neutral (Overweight) |
8.66 (11.16) |
28.87% | Details | |
| 7/12/2022 | Vera Therapeutics | VERA | New Coverage | Overweight (N/A) |
14.69 (38.20) |
160.04% | Details | |
| 5/27/2022 | Spring Works Therapeutics | SWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/12/2022 | Nuvalent | NUVL | Maintain | Overweight (N/A) |
|
Details | ||
| 5/11/2022 | Rapt Therapeutics | RAPT | Maintain | Overweight (N/A) |
|
Details | ||
| 5/10/2022 | Spring Works Therapeutics | SWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/10/2022 | ChemoCentryx | CCXI | Maintain | Neutral (N/A) |
|
Details | ||
| 5/5/2022 | CytomX Therapeutics | CTMX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/28/2022 | Atara Biotherapeutics | ATRA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/18/2022 | AnaptysBio | ANAB | Maintain | Underweight (N/A) |
|
Details | ||
| 3/15/2022 | Ideaya Biosciences | IDYA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/11/2022 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 3/9/2022 | Day One Biopharmaceuticals | DAWN | Maintain | Overweight (N/A) |
|
Details | ||
| 3/9/2022 | Aeglea Biotherapeutics | AGLE | Maintain | Overweight (N/A) |
|
Details | ||
| 3/8/2022 | Passage Bio Inc. | PASG | Downgrade | Neutral (Overweight) |
2.93 (6.12) |
108.87% | Details | |
| 3/3/2022 | ChemoCentryx | CCXI | Maintain | Neutral (N/A) |
|
Details | ||
| 3/1/2022 | Protagonist Therapeutics | PTGX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/1/2022 | Mirati Therapeutics | MRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/25/2022 | Spring Works Therapeutics | SWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/25/2022 | Amicus Therapeutics | FOLD | Maintain | Overweight (N/A) |
|
Details | ||
| 2/25/2022 | Theravance Biopharma | TBPH | Maintain | Neutral (N/A) |
|
Details | ||
| 2/24/2022 | Kodiak Sciences Inc. | KOD | Downgrade | Neutral (Overweight) |
9.86 (37.05) |
275.76% | Details | |
| 2/16/2022 | Mirati Therapeutics | MRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/14/2022 | Generation Bio | GBIO | Maintain | Neutral (N/A) |
|
Details | ||
| 2/2/2022 | Kodiak Sciences Inc. | KOD | Upgrade | Overweight (Neutral) |
58.70 (37.05) |
-36.88% | Details | |
| 12/14/2021 | Generation Bio | GBIO | Downgrade | Neutral (Overweight) |
13.90 (5.34) |
-61.58% | Details | |
| 12/10/2021 | Cytokinetics | CYTK | New Coverage | Overweight (N/A) |
37.05 (80.01) |
115.95% | Details | |
| 12/9/2021 | Rapt Therapeutics | RAPT | New Coverage | Overweight (N/A) |
30.80 (58.02) |
88.38% | Details | |
| 11/24/2021 | Kodiak Sciences Inc. | KOD | Maintain | Neutral (N/A) |
|
Details | ||
| 11/19/2021 | BioAtla Inc. | BCAB | Maintain | Overweight (N/A) |
|
Details | ||
| 11/18/2021 | Protagonist Therapeutics | PTGX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/17/2021 | Neurocrine Bio. | NBIX | Upgrade | Overweight (Neutral) |
87.78 (161.44) |
83.91% | Details | |
| 11/16/2021 | Orchard Therapeutics | ORTX | Downgrade | Underweight (Neutral) |
1.77 (16.70) |
843.5% | Details | |
| 11/9/2021 | Oyster Point Pharma | OYST | Downgrade | Neutral (Overweight) |
14.12 (11.17) |
-20.89% | Details | |
| 11/5/2021 | Theravance Biopharma | TBPH | Upgrade | Neutral (Underweight) |
8.08 (16.97) |
110.02% | Details | |
| 11/5/2021 | Sarepta Therapeutics | SRPT | Upgrade | Overweight (Neutral) |
86.53 (13.32) |
-84.61% | Details | |
| 11/4/2021 | G1 Therapeutics | GTHX | Downgrade | Underweight (Neutral) |
16.16 (7.15) |
-55.75% | Details | |
| 11/2/2021 | Kiniksa | KNSA | Maintain | Overweight (N/A) |
|
Details | ||
| 10/25/2021 | Vir Biotechnology | VIR | Upgrade | Neutral (Underweight) |
39.93 (10.16) |
-74.56% | Details | |
| 10/12/2021 | Protagonist Therapeutics | PTGX | Upgrade | Overweight (Neutral) |
18.24 (118.96) |
552.19% | Details | |
| 10/11/2021 | ChemoCentryx | CCXI | Upgrade | Neutral (Underweight) |
38.41 (10.42) |
-72.87% | Details | |
| 9/30/2021 | G1 Therapeutics | GTHX | Downgrade | Neutral (Overweight) |
15.40 (7.15) |
-53.57% | Details | |
| 9/30/2021 | Amicus Therapeutics | FOLD | Upgrade | Overweight (Neutral) |
10.18 (14.49) |
42.34% | Details | |
| 9/20/2021 | Protagonist Therapeutics | PTGX | Downgrade | Neutral (Overweight) |
46.13 (118.96) |
157.88% | Details | |
| 9/15/2021 | Theravance Biopharma | TBPH | Downgrade | Underweight (Overweight) |
8.04 (16.97) |
111.07% | Details | |
| 9/8/2021 | Spring Works Therapeutics | SWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/7/2021 | Mirati Therapeutics | MRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/26/2021 | ChemoCentryx | CCXI | Maintain | Underweight (N/A) |
|
Details | ||
| 8/25/2021 | Ideaya Biosciences | IDYA | Maintain | Overweight (N/A) |
|
Details | ||
| 8/24/2021 | ORIC Pharamceuticals | ORIC | Maintain | Overweight (N/A) |
|
Details | ||
| 8/24/2021 | Kiniksa | KNSA | Maintain | Overweight (N/A) |
|
Details | ||
| 8/23/2021 | Annexon Biosciences | ANNX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/23/2021 | Aeglea Biotherapeutics | AGLE | Maintain | Overweight (N/A) |
|
Details | ||
| 8/23/2021 | Allovir Inc. | ALVR | Maintain | Overweight (N/A) |
|
Details | ||
| 8/23/2021 | Nuvalent | NUVL | New Coverage | Overweight (N/A) |
26.40 (88.49) |
235.19% | Details | |
| 8/18/2021 | CytomX Therapeutics | CTMX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/18/2021 | BioAtla Inc. | BCAB | Maintain | Overweight (N/A) |
|
Details | ||
| 8/18/2021 | Orchard Therapeutics | ORTX | Downgrade | Neutral (Overweight) |
2.69 (16.70) |
520.82% | Details | |
| 8/17/2021 | Oyster Point Pharma | OYST | Maintain | Overweight (N/A) |
|
Details | ||
| 8/16/2021 | Day One Biopharmaceuticals | DAWN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/10/2021 | Erasca Inc | ERAS | New Coverage | Overweight (N/A) |
20.99 (15.07) |
-28.2% | Details | |
| 8/5/2021 | Sarepta Therapeutics | SRPT | Upgrade | Neutral (Underweight) |
69.04 (17.26) |
-75% | Details | |
| 8/2/2021 | Infinity Pharmaceutical | INFI | Upgrade | Overweight (Neutral) |
2.33 (0.04) |
-98.28% | Details | |
| 7/20/2021 | Elevation Oncology | ELEV | New Coverage | Overweight (N/A) |
12.10 (0.37) |
-96.94% | Details | |
| 7/13/2021 | Cytier Therapeutics | CYT | New Coverage | Overweight (N/A) |
18.89 (3.02) |
-84.01% | Details | |
| 7/2/2021 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (N/A) |
|
Details | ||
| 6/30/2021 | Orchard Therapeutics | ORTX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/21/2021 | Day One Biopharmaceuticals | DAWN | New Coverage | Overweight (N/A) |
19.46 (21.33) |
9.61% | Details | |
| 6/11/2021 | Protagonist Therapeutics | PTGX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/2/2021 | Constellation Pharmaceuticals | CNST | Downgrade | Neutral (Overweight) |
20.24 (33.99) |
67.93% | Details | |
| 6/1/2021 | Orchard Therapeutics | ORTX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/14/2021 | iTeos Therapeutics | ITOS | Maintain | Overweight (N/A) |
|
Details | ||
| 5/13/2021 | Atara Biotherapeutics | ATRA | Upgrade | Overweight (Neutral) |
13.91 (11.16) |
-19.77% | Details | |
| 5/12/2021 | Spring Works Therapeutics | SWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/11/2021 | Oyster Point Pharma | OYST | Maintain | Overweight (N/A) |
|
Details | ||
| 5/11/2021 | Kodiak Sciences Inc. | KOD | Maintain | Neutral (N/A) |
|
Details | ||
| 5/11/2021 | Allovir Inc. | ALVR | Maintain | Overweight (N/A) |
|
Details | ||
| 5/7/2021 | Mirati Therapeutics | MRTX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/7/2021 | ChemoCentryx | CCXI | Downgrade | Underweight (Neutral) |
27.49 (10.42) |
-62.1% | Details | |
| 5/6/2021 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 5/6/2021 | Theravance Biopharma | TBPH | Maintain | Overweight (N/A) |
|
Details | ||
| 5/6/2021 | AnaptysBio | ANAB | Maintain | Underweight (N/A) |
|
Details | ||
| 5/6/2021 | Atara Biotherapeutics | ATRA | Maintain | Neutral (N/A) |
|
Details | ||
| 4/16/2021 | Ideaya Biosciences | IDYA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/29/2021 | CytomX Therapeutics | CTMX | New Coverage | Overweight (N/A) |
7.94 (3.15) |
-60.33% | Details | |
| 3/23/2021 | Frequency Therapeutics | FREQ | Downgrade | Underweight (Overweight) |
36.29 (0.30) |
-99.17% | Details | |
| 3/19/2021 | Olema Pharmaceuticals | OLMA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/19/2021 | Idera Pharmaceuticals | IDRA | Downgrade | Neutral (Overweight) |
5.13 (0.43) |
-91.62% | Details | |
| 3/8/2021 | AnaptysBio | ANAB | Downgrade | Underweight (Overweight) |
29.47 (59.43) |
101.66% | Details | |
| 3/2/2021 | Orchard Therapeutics | ORTX | New Coverage | Overweight (N/A) |
6.97 (16.70) |
139.6% | Details | |
| 2/22/2021 | BridgeBio Pharma | BBIO | New Coverage | Overweight (N/A) |
63.85 (68.63) |
7.49% | Details | |
| 2/16/2021 | G1 Therapeutics | GTHX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/11/2021 | AnaptysBio | ANAB | Upgrade | Overweight (Neutral) |
29.61 (29.47) |
-0.47% | Details | |
| 2/5/2021 | Infinity Pharmaceutical | INFI | Upgrade | Neutral (Underweight) |
3.70 (0.04) |
-98.92% | Details | |
| 1/27/2021 | Frequency Therapeutics | FREQ | Upgrade | Overweight (Neutral) |
37.83 (36.29) |
-4.07% | Details | |
| 1/27/2021 | Vir Biotechnology | VIR | Downgrade | Underweight (Neutral) |
44.39 (10.16) |
-77.11% | Details | |
| 1/8/2021 | Sarepta Therapeutics | SRPT | Downgrade | Underweight (Overweight) |
168.95 (17.26) |
-89.78% | Details | |
| 1/4/2021 | Passage Bio Inc. | PASG | Upgrade | Overweight (Neutral) |
25.57 (6.12) |
-76.07% | Details | |
| 11/30/2020 | Kodiak Sciences Inc. | KOD | Downgrade | Neutral (Overweight) |
132.20 (37.05) |
-71.97% | Details | |
| 11/10/2020 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 11/6/2020 | Oyster Point Pharma | OYST | Maintain | Overweight (N/A) |
|
Details | ||
| 10/29/2020 | ChemoCentryx | CCXI | Downgrade | Neutral (Overweight) |
52.44 (10.42) |
-80.13% | Details | |
| 10/5/2020 | MyoKardia | MYOK | Downgrade | Neutral (Overweight) |
139.60 (224.91) |
61.11% | Details | |
| 9/11/2020 | Vir Biotechnology | VIR | Upgrade | Neutral (Underweight) |
30.17 (10.16) |
-66.32% | Details | |
| 8/25/2020 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 8/24/2020 | Allovir Inc. | ALVR | New Coverage | Overweight (N/A) |
30.85 (9.81) |
-68.2% | Details | |
| 8/17/2020 | Annexon Biosciences | ANNX | New Coverage | Overweight (N/A) |
26.17 (5.28) |
-79.82% | Details | |
| 8/17/2020 | iTeos Therapeutics | ITOS | New Coverage | Overweight (N/A) |
31.40 (10.15) |
-67.68% | Details | |
| 8/14/2020 | Passage Bio Inc. | PASG | Downgrade | Neutral (Overweight) |
14.77 (25.57) |
73.12% | Details | |
| 8/13/2020 | Spring Works Therapeutics | SWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/11/2020 | ChemoCentryx | CCXI | Maintain | Overweight (N/A) |
|
Details | ||
| 8/11/2020 | Generation Bio | GBIO | Maintain | Neutral (N/A) |
|
Details | ||
| 8/5/2020 | MyoKardia | MYOK | Maintain | Overweight (N/A) |
|
Details | ||
| 8/5/2020 | Oyster Point Pharma | OYST | Maintain | Overweight (N/A) |
|
Details | ||
| 8/4/2020 | Neurocrine Bio. | NBIX | Downgrade | Neutral (Overweight) |
120.36 (161.44) |
34.13% | Details | |
| 7/17/2020 | Kiniksa | KNSA | Maintain | Overweight (N/A) |
|
Details | ||
| 7/13/2020 | Ideaya Biosciences | IDYA | Upgrade | Overweight (Neutral) |
13.34 (34.91) |
161.69% | Details | |
| 7/7/2020 | Generation Bio | GBIO | New Coverage | Overweight (N/A) |
19.56 (13.90) |
-28.94% | Details | |
| 7/7/2020 | Theravance Biopharma | TBPH | New Coverage | Overweight (N/A) |
20.52 (8.04) |
-60.82% | Details | |
| 6/29/2020 | Kiniksa | KNSA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/18/2020 | Frequency Therapeutics | FREQ | Downgrade | Neutral (Overweight) |
16.99 (37.83) |
122.66% | Details | |
| 5/14/2020 | Eidos Therapeutics | EIDX | Downgrade | Neutral (Overweight) |
41.09 (122.21) |
197.42% | Details | |
| 5/7/2020 | Alnylam Pharmaceuticals | ALNY | Downgrade | Neutral (Overweight) |
141.23 (253.54) |
79.52% | Details | |
| 5/1/2020 | Mirati Therapeutics | MRTX | Upgrade | Overweight (Neutral) |
87.80 (58.70) |
-33.14% | Details | |
| 3/24/2020 | Passage Bio Inc. | PASG | New Coverage | Overweight (N/A) |
9.79 (6.12) |
-37.49% | Details | |
| 3/20/2020 | Zai Lab | ZLAB | Maintain | Overweight (N/A) |
|
Details | ||
| 3/19/2020 | Vir Biotechnology | VIR | Downgrade | Underweight (Neutral) |
50.26 (10.16) |
-79.79% | Details | |
| 3/18/2020 | Spring Works Therapeutics | SWTX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/17/2020 | Kodiak Sciences Inc. | KOD | Maintain | Overweight (N/A) |
|
Details | ||
| 3/12/2020 | Mirati Therapeutics | MRTX | Upgrade | Neutral (Underweight) |
86.58 (87.80) |
1.41% | Details | |
| 3/2/2020 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 2/18/2020 | ChemoCentryx | CCXI | Maintain | Overweight (N/A) |
|
Details | ||
| 2/13/2020 | Agios Pharma | AGIO | Maintain | Overweight (N/A) |
|
Details | ||
| 2/4/2020 | Vir Biotechnology | VIR | Downgrade | Neutral (Overweight) |
26.63 (50.26) |
88.73% | Details | |
| 12/24/2019 | Kodiak Sciences Inc. | KOD | New Coverage | Overweight (N/A) |
67.03 (37.05) |
-44.73% | Details | |
| 12/24/2019 | Y-mAbs Therapeutics | YMAB | New Coverage | Overweight (N/A) |
31.75 (8.61) |
-72.88% | Details | |
| 12/5/2019 | Audentes Therapeutics | BOLD | Downgrade | Neutral (Overweight) |
59.30 (2.60) |
-95.62% | Details | |
| 11/26/2019 | ChemoCentryx | CCXI | Maintain | Overweight (N/A) |
|
Details | ||
| 11/25/2019 | Alnylam Pharmaceuticals | ALNY | Maintain | Overweight (N/A) |
|
Details | ||
| 11/22/2019 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (N/A) |
|
Details | ||
| 11/8/2019 | AnaptysBio | ANAB | Downgrade | Underweight (Overweight) |
36.16 (59.43) |
64.35% | Details | |
| 11/8/2019 | Atara Biotherapeutics | ATRA | Downgrade | Neutral (Overweight) |
12.16 (11.16) |
-8.22% | Details | |
| 11/5/2019 | Vir Biotechnology | VIR | New Coverage | Overweight (N/A) |
15.00 (10.16) |
-32.27% | Details | |
| 10/28/2019 | Frequency Therapeutics | FREQ | New Coverage | Overweight (N/A) |
14.05 (0.30) |
-97.86% | Details | |
| 10/16/2019 | Mirati Therapeutics | MRTX | Maintain | Underweight (N/A) |
|
Details | ||
| 10/8/2019 | Spring Works Therapeutics | SWTX | New Coverage | Overweight (N/A) |
18.15 (46.99) |
158.9% | Details | |
| 10/3/2019 | Dova Pharmaceuticals Inc | DOVA | Upgrade | Neutral (Underweight) |
27.87 (28.04) |
0.61% | Details | |
| 9/12/2019 | ChemoCentryx | CCXI | Upgrade | Overweight (Neutral) |
7.59 (10.42) |
37.29% | Details | |
| 8/8/2019 | G1 Therapeutics | GTHX | Upgrade | Overweight (Neutral) |
23.48 (7.15) |
-69.55% | Details | |
| 8/2/2019 | Mirati Therapeutics | MRTX | New Coverage | Underweight (N/A) |
105.80 (58.70) |
-44.52% | Details | |
| 7/12/2019 | Replimune Group | REPL | Upgrade | Overweight (Neutral) |
13.93 (11.42) |
-18.02% | Details | |
| 7/12/2019 | Apellis Pharmaceuticals | APLS | Upgrade | Overweight (Neutral) |
26.88 (41.03) |
52.64% | Details | |
| 4/22/2019 | Neurocrine Bio. | NBIX | Upgrade | Overweight (Neutral) |
78.43 (161.44) |
105.84% | Details | |
| 4/17/2019 | Mirati Therapeutics | MRTX | New Coverage | Neutral (N/A) |
65.18 (105.80) |
62.32% | Details | |
| 3/21/2019 | Aeglea Biotherapeutics | AGLE | New Coverage | Overweight (N/A) |
8.25 (12.01) |
45.58% | Details | |
| 3/1/2019 | Rigel Pharmaceuticals | RIGL | Maintain | Overweight (N/A) |
|
Details | ||
| 2/27/2019 | Eidos Therapeutics | EIDX | Upgrade | Overweight (Neutral) |
17.51 (122.21) |
597.94% | Details | |
| 2/21/2019 | Zai Lab | ZLAB | Maintain | Overweight (N/A) |
|
Details | ||
| 1/23/2019 | Replimune Group | REPL | Downgrade | Neutral (Overweight) |
10.45 (13.93) |
33.3% | Details | |
| 1/23/2019 | Neurocrine Bio. | NBIX | Downgrade | Neutral (Overweight) |
91.53 (78.43) |
-14.31% | Details | |
| 1/23/2019 | La Jolla Pharma | LJPC | Upgrade | Neutral (Underweight) |
6.30 (6.22) |
-1.27% | Details | |
| 1/23/2019 | G1 Therapeutics | GTHX | Downgrade | Neutral (Overweight) |
20.13 (23.48) |
16.64% | Details | |
| 1/23/2019 | Eidos Therapeutics | EIDX | Downgrade | Neutral (Overweight) |
12.65 (17.51) |
38.42% | Details | |
| 1/23/2019 | Dova Pharmaceuticals Inc | DOVA | Downgrade | Underweight (Overweight) |
8.23 (27.87) |
238.64% | Details | |
| 1/23/2019 | Apellis Pharmaceuticals | APLS | Downgrade | Neutral (Overweight) |
13.44 (26.88) |
100% | Details | |
| 12/12/2018 | Neurocrine Bio. | NBIX | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/26/2018 | Orchard Therapeutics | ORTX | New Coverage | Overweight (N/A) |
16.04 (16.70) |
4.11% | Details | |
| 11/26/2018 | Audentes Therapeutics | BOLD | New Coverage | Overweight (N/A) |
24.01 (59.30) |
146.98% | Details | |
| 11/21/2018 | AnaptysBio | ANAB | New Coverage | Overweight (N/A) |
67.80 (36.16) |
-46.67% | Details | |
| 11/12/2018 | Infinity Pharmaceutical | INFI | Downgrade | Underweight (Neutral) |
2.41 (0.04) |
-98.34% | Details | |
| 10/8/2018 | Dynavax Technologies | DVAX | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/27/2018 | Eidos Therapeutics | EIDX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/15/2018 | Idera Pharmaceuticals | IDRA | New Coverage | Overweight (N/A) |
7.39 (0.43) |
-94.18% | Details | |
| 8/14/2018 | Replimune Group | REPL | New Coverage | Overweight (N/A) |
16.91 (10.45) |
-38.2% | Details | |
| 8/14/2018 | ChemoCentryx | CCXI | Downgrade | Neutral (Overweight) |
11.95 (7.59) |
-36.49% | Details | |
| 8/13/2018 | Constellation Pharmaceuticals | CNST | New Coverage | Overweight (N/A) |
9.87 (20.24) |
105.07% | Details |
